CIPLA LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,494 INR | +0.95% |
|
+0.76% | +19.84% |
| May. 27 | Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research | RE |
| May. 23 | Nomura Adjusts Cipla’s Price Target to INR1,535 From INR1,486, Keeps at Neutral | MT |
| Sales 2024 | 258B 3.09B | Sales 2025 * | 280B 3.37B | Capitalization | 1,195B 14.34B |
|---|---|---|---|---|---|
| Net income 2024 | 41.22B 495M | Net income 2025 * | 46.6B 559M | EV / Sales 2024 | 4.69 x |
| Net cash position 2024 * | 55.83B 670M | Net cash position 2025 * | 57.78B 694M | EV / Sales 2025 * | 4.05 x |
| P/E ratio 2024 |
29.3
x | P/E ratio 2025 * |
25.7
x | Employees | 32,323 |
| Yield 2024 * |
0.57% | Yield 2025 * |
0.67% | Free-Float | 67.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cipla Limited
More recommendations
More press releases
More news
| 1 day | +0.78% | ||
| 1 week | +0.59% | ||
| Current month | +6.50% | ||
| 1 month | +5.90% | ||
| 3 months | +0.72% | ||
| 6 months | +24.09% | ||
| Current year | +19.64% |
1 week
1 462.70
1 504.55
1 month
1 317.251 504.55
Current year
1 252.101 519.00
1 year
942.301 519.00
3 years
850.001 519.00
5 years
355.301 519.00
10 years
355.301 519.00
| Managers | Title | Age | Since |
|---|---|---|---|
Umang Vohra
CEO | Chief Executive Officer | 52 | 15-09-30 |
Ashish Adukia
DFI | Director of Finance/CFO | - | 22-08-15 |
Geena Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 85-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ashok K. Sinha
BRD | Director/Board Member | 72 | 13-07-15 |
| Chairman | 87 | 72-07-20 | |
| Director/Board Member | 83 | 77-08-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.99% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-29 | 1,494 | +0.95% | 1 607 691 |
| 24-05-28 | 1,479 | +0.05% | 784,496 |
| 24-05-27 | 1,479 | -0.52% | 1,393,334 |
| 24-05-24 | 1,486 | -0.18% | 758,326 |
| 24-05-23 | 1,489 | +0.46% | 4,389,470 |
Delayed Quote NSE India S.E., May 29, 2024 at 03:56 am EDT
More quotes
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.
Net sales by source of income break down between sale of products (96.9%) and services (3.1%).
Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Sector
Pharmaceuticals
Calendar
2024-08-01
- Ex-dividend day for final dividend
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
1,479
INR
Average target price
1,476
INR
Spread / Average Target
-0.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.64% | 14.36B | |
| +18.30% | 42.25B | |
| +15.37% | 21.27B | |
| +19.44% | 15.23B | |
| +51.80% | 12.74B | |
| -0.05% | 6.79B | |
| -12.40% | 6.61B | |
| -8.87% | 5.73B | |
| +14.28% | 5.66B | |
| +7.31% | 4.8B |
- Stock Market
- Equities
- CIPLA Stock
